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In this issue of the European Journal of Preventative Cardiology, Langseth et al. suggest yet another marker for risk. 2 Thrombosis contributes causally to the complications of many common cardiovascular conditions including atherosclerosis, venous thromboembolism and atrial fibrillation. Over the past several years, we have learned much about the role neutrophils may play in this process. Polymorphonuclear leukocytes (PMNs) comprise a major component of the circulating immune system. Traditionally thought of as defenders against foreign invaders, they also play roles in thrombosis. We now appreciate that PMNs generate neutrophil extracellular traps (NETs), which participate in venous and arterial thrombosis. 3 NETs consist of strands of DNA, to which primitive defense proteins may attach, derived from the neutrophil itself (e.g. myeloperoxidase), or from the circulation (e.g. tissue factor procoagulant). NETs can also entrap circulating platelets, fibrin strands and von Willebrand factor, forming a scaffold for clot formation.
Earlier studies have shown that PMNs, and more specifically NETs, associate with thrombus formation in patients undergoing acute myocardial infarction. 4 PMNs taken from the culprit lesion during an acute coronary syndrome are highly activated and readily undergo NETosis. 5 Our group found that PMNs associate with human atheromata with morphologies characteristic of those complicated by superficial erosion. Studies in vitro suggest that PMNs potentiate endothelial apoptosis and detachment. 6 Antineutrophil cytoplasmic antibodies recognize components of NETs, including proteinase 3 and myeloperoxidase, and are likely to participate causally in forms of vasculitis. 7 These observations implicate neutrophil dysregulation in a variety of vascular diseases, not only coronary artery disease (CAD), but also ischemic stroke, venous thrombosis and vasculitides. 8 Taken together, good evidence now establishes that neutrophils participate importantly in a large swath of cardiovascular diseases ( Figure 1 ).
Langseth et al. 2 show that serum markers of NETosis, including double-stranded DNA (dsDNA), can predict cardiovascular events. They began with a cohort of patients with stable CAD and followed them for at least two years. Those with the highest three quartiles of dsDNA had double the risk of experiencing a clinical endpoint, including unstable angina, nonhemorrhagic stroke, myocardial infarction, or death. The authors also show an association of higher dsDNA levels with known cardiovascular risk factors, including male sex, smoking, metabolic syndrome and a history of myocardial infarction.
Despite the apparent stability of these CAD patients, the data presented by Langseth et al. 2 suggest the presence of chronic NET activity perhaps related to plaque disruptions that occur below the threshold of clinical detection. Such events appear common. 9 This concept of ongoing subclinical plaque complications could have important implications for secondary prevention as it places additional emphasis on anticoagulation and antiplatelet therapy. Patients with stable CAD should receive a guideline-recommended cocktail of medications, including antiplatelet therapy, beta blockers and statins. The recently published COMPASS trial examined the benefit of low-dose rivaroxaban, a direct oral anticoagulant, in addition to aspirin in patients with stable coronary or peripheral artery disease. 10 The results suggest a reduction in cardiovascular events in patients on a combination of low-dose anticoagulation and antiplatelet therapy. Certain patients with chronic, subclinical NET activity may benefit from the addition of an anticoagulant. More precise allocation of such therapy would be welcome, however, as patients on low-dose rivaroxaban also have a higher risk of major bleeding. The 'personalized' approach of assessing the degree of continued microdisruptions of plaques in seemingly stable patients as assessed by biomarkers could help allocate such powerful therapies in a more targeted and rational manner.
Langseth et al. 2 provide new evidence for chronic NETosis as a risk factor for cardiovascular events, yet many questions remain unanswered. Myeloperoxidase, a recognized inflammatory protein linked to NETs, did not associate with either hypercoagulability or clinical endpoints in this patient cohort. Furthermore, dsDNA was only modestly elevated in those patients in the three highest quartiles. This finding could result from aggregation of the data, in which patients with the highest NET activity were combined with those with no activity at all. The authors correctly suggest that we need further research into biomarkers that would correlate with NET activity. Alternative markers could include the products of eroded plaques, which may more reliably reflect the risk of thrombosis.
11
As we learn more about the role of neutrophils in cardiovascular disease, we gain insights into the function these common constituents of the innate immune system have in maintaining health. We have recognized many common risk factors for cardiovascular disease for more than 60 years since the initial reports of the Framingham Study, yet we may soon also include markers of chronic thrombosis. Further investigation into this growing area of cardiovascular medicine is certainly on the way, and the results of the study by Langseth et al. 2 furnish a welcome step in this direction.
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